Telescope Deepens Ties With Automation Leader to Advance Self-Driving Labs

Telescope Innovations Corp ( (TSE:TELI) ) has provided an announcement.

Telescope Innovations has expanded the consulting role of Dr. Joel M. Hawkins, a leading figure in process chemistry automation, to deepen his involvement across its automated reaction sampling and autonomous lab platforms. Hawkins, known for his work at Pfizer and Technobis applying automation, parallel experimentation, and data-rich analytics to accelerate process development, has already contributed to Telescope’s lithium-sector process IP and will now help advance its flagship DirectInject-LC platform and collaboration with AGI on next-generation reactors.

The enhanced engagement will also see Hawkins support Telescope’s Self-Driving Laboratories, which integrate robotics, inline analytics, and artificial intelligence to perform chemistry research more efficiently than traditional methods, with deployments already at Pfizer and in South Korea’s pharma and biopharma sector. Management highlights the move as a way to push the boundaries of automated experimentation, strengthen Telescope’s position in high-value chemical and biopharma R&D workflows, and potentially shorten development timelines and costs for customers adopting these advanced platforms.

More about Telescope Innovations Corp

Telescope Innovations Corp. is a Vancouver-based developer of reaction sampling technology, intelligent automation, and advanced chemical manufacturing solutions for the global pharmaceutical, high-value specialty chemical, and advanced materials industries. Its portfolio includes real-time reaction sampling systems, flexible robotic platforms, and AI-driven “Self-Driving Labs” that aim to accelerate and de-risk process development from lab to market.

Average Trading Volume: 134,132

Technical Sentiment Signal: Sell

Current Market Cap: C$27.86M

For a thorough assessment of TELI stock, go to TipRanks’ Stock Analysis page.